The influence of dosing schedules and cerebrospinal fluid bactericidal activity on the therapy of bacterial meningitis.
Bacterial meningitis represents an infection in an area of impaired host defence. Optimal therapy of meningitis requires attaining bactericidal activity within cerebrospinal fluid (CSF). Studies in experimental animal models of meningitis suggest that maximal rates of bacterial killing in vivo and optimal cure rates are achieved when CSF antibiotic concentrations exceed the MBC of the test strain by greater than or equal to ten-fold. The results of clinical trials support this conclusion. In addition, a variable post-antibiotic effect occurs in-vivo after short periods of exposure to antimicrobial activity, thus maintaining therapeutic efficacy with intermittent dosage regimens. These basic principles of therapy are outlined in this review and serve as a basis for rational treatment regimens. For most antibiotics, the optimal dose, dosage interval, and duration of therapy for bacterial meningitis remain to be established.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000134:cerebrospinal fluid; D001424:Bacterial Infections / Q000188:drug therapy*; D002555:Cerebrospinal Fluid / Q000502:physiology*; D004334:Drug Administration Schedule; D008581:Meningitis / Q000188:drug therapy*; D011817:Rabbits
D000900:Anti-Bacterial Agents